StockData
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Bicara Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$17.47+0.69 (+4.11%)

Close on Oct 19, 2026

Market cap
$1.19B
P/E (TTM)
–
Dividend yield
–

SEC filings

30 of Bicara Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KAug 21, 2026Aug 25, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 11, 2026SEC EDGAR
Current report8-KAug 11, 2026Aug 11, 2026SEC EDGAR
Current report8-KJul 23, 2026Jul 28, 2026SEC EDGAR
Current report8-KJun 9, 2026Jun 10, 2026SEC EDGAR
Current report8-KMay 21, 2026May 21, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 11, 2026SEC EDGAR
Current report8-KMay 11, 2026May 11, 2026SEC EDGAR
Proxy statementDEF 14AApr 21, 2026Apr 27, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 30, 2026SEC EDGAR
Current report8-KMar 30, 2026Mar 30, 2026SEC EDGAR
Current report8-KFeb 24, 2026Feb 26, 2026SEC EDGAR
Current report8-KFeb 19, 2026Feb 19, 2026SEC EDGAR
Current report8-KJan 12, 2026Jan 12, 2026SEC EDGAR
Current report8-KDec 6, 2025Dec 8, 2025SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 10, 2025SEC EDGAR
Current report8-KNov 10, 2025Nov 10, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 12, 2025SEC EDGAR
Current report8-KAug 12, 2025Aug 12, 2025SEC EDGAR
Current report8-KJun 9, 2025Jun 12, 2025SEC EDGAR
Current report8-KJun 2, 2025Jun 6, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 13, 2025SEC EDGAR
Current report8-KMay 13, 2025May 13, 2025SEC EDGAR
Proxy statementDEF 14AJun 9, 2025Apr 25, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 27, 2025SEC EDGAR
Current report8-KMar 27, 2025Mar 27, 2025SEC EDGAR
Current report8-KJan 13, 2025Jan 13, 2025SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 12, 2024SEC EDGAR
Current report8-KNov 12, 2024Nov 12, 2024SEC EDGAR
Current report8-KSep 12, 2024Sep 16, 2024SEC EDGAR